R1 RCM Financials
RCM Stock | USD 14.31 0.01 0.07% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Debt Equity Ratio | 0.57 | 0.5973 |
|
| |||||
Current Ratio | 1.09 | 1.8293 |
|
|
The essential information of the day-to-day investment outlook for R1 RCM includes many different criteria found on its balance sheet. An individual investor should monitor R1 RCM's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in R1 RCM.
Net Income |
|
RCM | Select Account or Indicator |
Understanding current and past R1 RCM Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of R1 RCM's financial statements are interrelated, with each one affecting the others. For example, an increase in R1 RCM's assets may result in an increase in income on the income statement.
R1 RCM Stock Summary
R1 RCM competes with National Research, Definitive Healthcare, HealthStream, Evolent Health, and CareMax. R1 RCM Inc. provides technology-driven solutions that transform the patient experience and financial performance of hospitals, health systems, and medical groups. The company was founded in 2003 and is headquartered in Murray, Utah. R1 Rcm operates under Health Information Services classification in the United States and is traded on NASDAQ Exchange. It employs 20800 people.Specialization | Health Care, Health Care Equipment & Services |
Instrument | USA Stock View All |
Exchange | NASDAQ Exchange |
ISIN | US7493971052 |
CUSIP | 77634L105 749397105 00438V103 |
Location | Illinois; U.S.A |
Business Address | 434 W Ascension |
Sector | Health Care Providers & Services |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | www.r1rcm.com |
Phone | 312 324 7820 |
Currency | USD - US Dollar |
R1 RCM Key Financial Ratios
Return On Equity | -0.022 | ||||
Profit Margin | (0.02) % | ||||
Operating Margin | 0.04 % | ||||
Price To Sales | 2.45 X | ||||
Revenue | 2.25 B |
R1 RCM Key Balance Sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 929.1M | 1.2B | 1.4B | 5.1B | 5.0B | 5.2B | |
Other Current Liab | 135.1M | 141.7M | 196M | 179.6M | 87.5M | 122.2M | |
Other Liab | 29M | 52.6M | 40.1M | 242.5M | 278.9M | 292.8M | |
Net Tangible Assets | (399.8M) | (207M) | (473.4M) | (1.5B) | (1.3B) | (1.2B) | |
Net Debt | 357.5M | 461.4M | 709.2M | 1.8B | 1.6B | 1.6B | |
Retained Earnings | (277.8M) | (161.5M) | (64.3M) | (121.9M) | (136.7M) | (143.5M) | |
Accounts Payable | 20.2M | 18.2M | 17.7M | 33.4M | 22.7M | 31.0M | |
Cash | 92M | 173.8M | 130.1M | 110.1M | 173.6M | 149.4M | |
Other Assets | 99.7M | 195M | 120.9M | 150.5M | 173.1M | 113.3M | |
Long Term Debt | 337.7M | 519.7M | 754.9M | 1.7B | 1.6B | 1.6B | |
Net Receivables | 83.1M | 122.2M | 162.9M | 344.1M | 379.5M | 398.5M | |
Good Will | 253.2M | 375.3M | 554.7M | 2.7B | 2.6B | 2.8B | |
Other Current Assets | 41.6M | 59.4M | 71.7M | 110.3M | 80.2M | 84.2M | |
Total Liab | 911M | 849.6M | 1.1B | 2.4B | 2.2B | 2.3B | |
Short Long Term Debt | 16.3M | 34.2M | 25.8M | 53.9M | 72.8M | 76.4M | |
Total Current Assets | 216.7M | 355.4M | 364.7M | 564.5M | 633.3M | 665.0M | |
Treasury Stock | (62.6M) | (73.6M) | (139.2M) | (215.2M) | (193.7M) | (184.0M) | |
Short Term Debt | 29.1M | 46.4M | 39.3M | 71.9M | 92.1M | 48.4M | |
Intangible Assets | 164.7M | 171.1M | 265.4M | 1.5B | 1.3B | 1.4B | |
Common Stock | 1.3M | 1.4M | 3M | 4.4M | 4.5M | 4.7M |
R1 RCM Key Income Statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Interest Expense | 29.1M | 17.3M | 18.9M | 64M | 126.9M | 133.2M | |
Total Revenue | 1.2B | 1.3B | 1.5B | 1.8B | 2.3B | 2.4B | |
Gross Profit | 198.3M | 249.7M | 311.8M | 361.3M | 484.5M | 508.7M | |
Operating Income | 112.7M | 80M | 145.7M | 3M | 147.9M | 155.3M | |
Ebit | 112.7M | 135.7M | 145.7M | 3M | 147.9M | 155.3M | |
Ebitda | 168.4M | 211.7M | 223.2M | 175M | 426.2M | 447.5M | |
Cost Of Revenue | 987.8M | 1.0B | 1.2B | 1.4B | 1.8B | 1.9B | |
Income Before Tax | 9.8M | 118.4M | 126.8M | (61M) | 21M | 39.3M | |
Net Income | 12M | 115.2M | 87.3M | (57.6M) | 3.3M | 3.1M | |
Income Tax Expense | (2.2M) | 1.3M | 29.6M | (3.4M) | 17.7M | 16.0M | |
Tax Provision | (2.2M) | 1.3M | 29.6M | (3.4M) | 5.8M | 10.7M | |
Net Interest Income | (29.1M) | (17.3M) | (18.9M) | (64M) | (124M) | (117.8M) |
R1 RCM Key Cash Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Change In Cash | 27.4M | 82.3M | (44.7M) | (20M) | 63.5M | 66.7M | |
Free Cash Flow | 52.9M | 12.5M | 213.1M | (103.4M) | 237.6M | 249.5M | |
Depreciation | 55.7M | 68.7M | 77.5M | 172M | 278.3M | 292.2M | |
Other Non Cash Items | 34.8M | (25.1M) | 9.3M | 57M | 74.1M | 77.8M | |
Capital Expenditures | 61M | 49.3M | 51.7M | 93.5M | 102.5M | 107.6M | |
Net Income | 12M | 117.1M | 97.2M | (57.6M) | 3.3M | 3.1M | |
End Period Cash Flow | 92.5M | 174.8M | 130.1M | 110.1M | 173.6M | 149.7M | |
Change To Inventory | (24.9M) | (1.2M) | (44M) | (11.4M) | (10.3M) | (9.7M) | |
Dividends Paid | 13.7M | 18.4M | 8.9M | 2.6M | 1.3M | 1.2M | |
Change To Netincome | 32.4M | (28.1M) | 95.4M | 113.7M | 130.8M | 137.3M | |
Change Receivables | (39.1M) | 11.5M | (56.5M) | (33.2M) | (29.9M) | (28.4M) | |
Investments | (61M) | (117M) | (340.4M) | (949.5M) | (103.2M) | (108.4M) | |
Net Borrowings | (7.2M) | 217.2M | 217.8M | 1.0B | 1.2B | 1.2B |
RCM Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining R1 RCM's current stock value. Our valuation model uses many indicators to compare R1 RCM value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across R1 RCM competition to find correlations between indicators driving R1 RCM's intrinsic value. More Info.R1 RCM Inc is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, R1 RCM's Return On Equity is very stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value R1 RCM by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.R1 RCM Inc Systematic Risk
R1 RCM's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. R1 RCM volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on R1 RCM Inc correlated with the market. If Beta is less than 0 R1 RCM generally moves in the opposite direction as compared to the market. If R1 RCM Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one R1 RCM Inc is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of R1 RCM is generally in the same direction as the market. If Beta > 1 R1 RCM moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in R1 RCM Stock are looking for potential investment opportunities by analyzing not only static indicators but also various R1 RCM's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of R1 RCM growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
R1 RCM November 22, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of R1 RCM help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of R1 RCM Inc. We use our internally-developed statistical techniques to arrive at the intrinsic value of R1 RCM Inc based on widely used predictive technical indicators. In general, we focus on analyzing RCM Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build R1 RCM's daily price indicators and compare them against related drivers.
Downside Deviation | 0.1582 | |||
Information Ratio | (0.44) | |||
Maximum Drawdown | 0.6415 | |||
Value At Risk | (0.21) | |||
Potential Upside | 0.2853 |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in R1 RCM Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of R1 RCM. If investors know RCM will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about R1 RCM listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.99) | Earnings Share (0.14) | Revenue Per Share 5.854 | Quarterly Revenue Growth 0.147 | Return On Assets 0.0235 |
The market value of R1 RCM Inc is measured differently than its book value, which is the value of RCM that is recorded on the company's balance sheet. Investors also form their own opinion of R1 RCM's value that differs from its market value or its book value, called intrinsic value, which is R1 RCM's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because R1 RCM's market value can be influenced by many factors that don't directly affect R1 RCM's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between R1 RCM's value and its price as these two are different measures arrived at by different means. Investors typically determine if R1 RCM is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, R1 RCM's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.